# Soleno Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/soleno-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Redwood City, US
- Website: www.soleno.life
- Total disclosed funding: $14M
- Latest round: Series B (Nov 1, 2006)
- Investors on record: 3

## About

Soleno Therapeutics, Inc, based in the US, is dedicated to developing innovative therapies for rare genetic disorders, focusing primarily on Prader-Willi syndrome with its flagship product, VykatXR.Founded in 1999 and headquartered in Redwood City, US, Soleno Therapeutics, Inc specializes in addressing rare genetic disorders. The company has undergone various funding rounds, with its most recent being a PIPE round in which it raised USD 60.00 mn. The firm was founded by Jordy Campagne and is currently led by CEO Anish Bhatnagar. The company has successfully raised a total of USD 60.00 mn over its history, with the latest funding round occurring on November 12, 2013. Soleno has completed 14 deals in total.Soleno Therapeutics focuses on developing therapies for rare genetic disorders, particularly with its core product, VykatXR, which is designed to help manage Prader-Willi syndrome (PWS). VykatXR is a long-acting formulation that aims to regulate appetite and improve the quality of life for patients suffering from PWS. Their customer base includes healthcare providers, hospitals, and specialty pharmacies across the United States, with plans to expand into international markets as regulatory approvals are obtained.In the most recent fiscal year 2016, Soleno Therapeutics reported revenue of USD 1,450,788 and an EBITDA of USD -185,684,000. The revenue stream is primarily generated from the sale of VykatXR through direct sales and partnerships with specialty pharmacies, ensuring efficient distribution to healthcare providers and hospitals.Soleno Therapeutics aims to enhance its growth through the development of new products and expansion into international markets. The company is focusing on launching additional therapies for rare genetic conditions, supported by recent funding of USD 60.00 mn. This funding will be utilized to expedite the development of VykatXR and facilitate entry into new markets, including Europe and Asia, over the next few years.

## Funding rounds

- Series B, Nov 1, 2006, $4.9M — Vivo Capital
- Series B, Sep 29, 2006, $1.1M — Teknoinvest Management
- Series B, May 4, 2004, $7.5M — Teknoinvest Management, Alliance Venture, Vivo Capital

## Investors

- Teknoinvest Management (https://capitalatlas.ai/funds/teknoinvest-management) — Series B
- Alliance Venture (https://capitalatlas.ai/funds/alliance-venture) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B